Skip to content

Conference Day One

Wednesday, December 11

8:30 Chair's Opening Remarks

Omar Khwaja
Chief Medical Officer & Head of Research & Development
Voyager Therapeutics

Gene Therapy: The Promising Future for Neurological Disorders

8.45 Beyond Small Molecules & Protein Therapeutics: New Modalities for Treatment of CNS Diseases

Natasha Penner
Director, Clinical Pharmacology & Pharmacometrics
Biogen

9.15 Speed Networking

This session is the ideal opportunity to meet face-to-face with the key thought leaders working in the neurological gene therapy field. Specifically designed to connect you with new contacts from the most active companies in the field, the renowned Speed Networking session will be one of the most valuable hours you spend at GTxN.

10.00 Morning Refreshments

Delivery, Delivery, Delivery: Accessing the CNS

11.00 Evaluating the Barriers to AAV Delivery into the Central Nervous System 

Robert Bell
Associate Research Fellow
Pfizer

11.30 Achieving Therapeutic AAV-based Gene Delivery to the Brain & Nervous System

Omar Khwaja
Chief Medical Officer & Head of Research & Development
Voyager Therapeutics

12.00 Lunch & Networking

Improving Specific Cell Targeting for More Efficient Cell Transduction

1.30 Impact of Capsid Engineering & Synthetic Components to Advance CNS Gene Therapy

Martin Childers
Chief Medical Officer
AskBio

2.00 Optimizing Targeting & Gene Expression: Defining Disease, Region & Cell Type

Lamya Shihabuddin
Head, Genetic Neurologic Diseases
Sanofi

2.30 Afternoon Refreshments & Networking

Improving the Efficiency of Gene Therapy Development

3.00 Aligning Preclinical Research with Current Regulation & Clinical Considerations

David Theron
Prospective & Opportunities Director, CNS
Servier

3.30 Achieving Clinical Progress while Establishing Mutually Beneficial Links with Academia

Gavin Corcoran
Chief Research & Development Officer
Axovant

4.00 Chair’s Closing Remarks

Omar Khwaja
Chief Medical Officer & Head of Research & Development
Voyager Therapeutics

4.15 Scientific Poster Session

The learning and networking continues at the Poster Session, an informal part of the conference agenda, allowing you to connect with your peers in a relaxed atmosphere and continue to forge new, beneficial relationships. You will have the opportunity to present and review presentations displaying new data from preclinical gene therapy research and clinical gene therapy progress in neurological disorders.